Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

Bone Marrow Transplantation

Volumn 28, Issue 9, 2001, Pages 859-863

  Morgan, R J ^a   Doroshow, J H ^a   Leong, L ^a   Schriber, J ^b   Shibata, S ^a   Forman, S ^a   Hamasaki, V ^a   Margolin, K ^a   Somlo, G ^a   Alvarnas, J ^b   McNamara, M ^a   Longmate, J ^a   Raschko, J ^a   Chow, W ^a   Vasilev, S ^a   McGonigle, K ^a   Yen, Y ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b City Hope Samaritan Bone Marrow T   (United States)

Author keywords

High dose chemotherapy; Ovarian cancer; Stem cell transplantation

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; NARCOTIC ANALGESIC AGENT;

ADULT; ARTICLE; AUTOTRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RECURRENCE; CANCER SURVIVAL; CARDIOTOXICITY; CAUSE OF DEATH; CLINICAL ARTICLE; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MEGADOSE; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; FEMALE; GRANULOCYTE; HEART EJECTION FRACTION; HUMAN; HUMAN CELL; INFECTION COMPLICATION; LEUKOCYTE COUNT; MUCOSA INFLAMMATION; NEUTROPENIA; OVARY CANCER; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; STEM CELL TRANSPLANTATION; SYMPTOMATOLOGY; THROMBOCYTE COUNT; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA;

EID: 0035201069     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1703243     Document Type: Article

References (28)

1. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: Final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer
2. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy
3. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: A randomized phase III study of the national cancer institute of Canada clinical trials group
4. The importance of dose intensity in the outcome of chemotherapy
5. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy
6. High-dose chemotherapy with autologous bone marrow transplantation in patients with refractory ovarian cancer
7. High dose melphalan and autologous marrow rescue in advanced epithelial ovarian carcinomas: A retrospective analysis of 35 patients treated in France
8. Clinical trial of etoposide and cisplatin as salvage therapy in advanced ovarian carcinoma
9. Therapy of ovarian carcinoma: The relationship of dose level and treatment intensity to survival
10. High-dose doxorubicin, etoposide, and cyclophosphamide with stem cell rein-fusion in patients with metastatic or high-risk primary breast cancer
11. Nonparametric estimation from incomplete observations
12. Cancer of the ovary
13. Chemotherapy of advanced ovarian cancer: Current status and future directions
14. NCCN ovarian cancer practice guidelines. The National Comprehensive Cancer Network
15. Randomized trial comparing two combination chemotherapy regimens (CHAP-5 v CP) in advanced ovarian carcinoma
16. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group Study
17. Cisplatin/paclitaxel vs carboplatin/paclitaxel in ovarian cancer: Update of an Arbeitsgemeinschaft Gynaekologische Onkologie Study Group trial
18. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer
19. Randomized phase III study of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: A Gynecologic Oncology Group trial
20. Impact of doxorubicin on survival in advanced ovarian cancer
21. Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer
22. The role of chemotherapy in the management of coelomic epithelial carcinoma of the ovary
23. Lack of improvement in survival in patients with relapsed or refractory epithelial ovarian cancer, 1980-1997
24. Dose intensity analysis of chemotherapy regimens in ovarian carcinoma
25. High-dose chemotherapy with autologous transplantation for persistent/relapsed ovarian cancer: A multivariate analysis of survival for 100 consecutively treated patients
26. High-dose chemotherapy with hematopoietic rescue in patients with stage III to IV ovarian cancer: Long-term results
27. High dose chemotherapy with autologous stem cell support in the treatment of patients with ovarian carcinoma
28. Phase III randomized trial of high dose chemotherapy (HDC) and peripheral blood stem cell (PBSC) support as consolidation in patients (pts) with responsive low-burden advanced ovarian cancer (AOC): Preliminary results GINECO/FNCLCC/SFGM-TC study